SAN JUAN, Puerto Rico,
July 28, 2017 /PRNewswire/
-- Abarca Health, a pharmacy benefit management (PBM) and
technology company that serves more than two million lives across
the nation, has signed a value-based reimbursement contract with
Biogen Inc. (NASDAQ: BIIB) for select products in Biogen's leading
multiple sclerosis (MS) portfolio. This first-of-its-kind agreement
between the companies offers an innovative approach to connecting
outcomes with the effective net cost of the products. The agreement
places accountability on Biogen to deliver safety, efficacy, and
value for the patients who receive these life-impacting therapies
and for the payers who finance them.
"We are excited to partner with Biogen in implementing this
innovative, data-driven, and outcomes-based pricing program for MS
drug therapies. We believe this program is a significant
milestone in our efforts to collaborate with pharmaceutical
manufacturers to find a better way to guide patients and payers
down the path to value, especially in high impact disease
categories," stated Javier Gonzalez,
Chief Operating Officer of Abarca Health.
This contract builds on Abarca Health's ongoing work with Biogen
to find better ways to collaborate in the treatment of patients
afflicted with complex, high-cost conditions.
"We believe that contracting approaches like this will help
expand access for patients. We are excited to work with an
innovative partner like Abarca Health and lead the way for MS
care," said Jean-Paul Kress, Executive Vice President and
President, International and Head of Global Therapeutic Operations
of Biogen.
Outcomes-based contracting is an important part of the future of
healthcare. By partnering with manufacturers such as Biogen, Abarca
Health is ensuring greater accountability around the investments
made by payers and patients in high cost treatments, which leads to
better access and better outcomes for patients.
About ABARCA HEALTH
As a pharmacy benefit management and technology company,
Abarca Health serves more than 2 million people across the
nation helping its clients manage over $1
billion per year in pharmaceutical spending. The
company leverages its people, culture and technology to develop
deep partnerships with health plans, government programs,
self-insuring employer/union groups, and other payers -
partnerships that are both authentic and flexible. By building
trust with and delivering consistently for its customers, Abarca is
able to better work together to create a healthcare experience that
cares for us like family, guides us on the path to value, and
inspires us to live better every day. For more information, please
visit www.abarcahealth.com.
View original
content:http://www.prnewswire.com/news-releases/abarca-health-announces-innovative-value-based-contract-with-biogen-for-multiple-sclerosis-therapies-300495968.html
SOURCE Abarca Health